Portage Biotech Inc (PTGEF) 0.1100 $PTGEF Portage

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Portage Biotech Inc (PTGEF) 0.1100 $PTGEF

Portage Announces Orphan Drug Designation Request Granted to Biohaven for BHV-4157
PR Newswire - Wed May 25, 8:24AM CDT
FDA Grants Biohaven Orphan Drug Designation for BHV-4157 for the Treatment of Patients with Spinocerebellar Ataxia (SCA)

Portage announces the appointment of Chief Commercial Officer at Biohaven
PR Newswire - Wed Apr 27, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven) has appointed John Tilton as Chief Commercial Officer. Mr. Tilton joined Biohaven from Alexion Pharmaceuticals, Inc. where he was an Executive Director and one of the founding commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. Tilton played a central role in the successful global launches of Soliris, as well as building operational infrastructure, for four orphan indication launches in over 30 countries for Alexion.
ALXN: 118.59 (+1.83)

Portage announcing results of its Annual Shareholder Meeting and other corporate matters
PR Newswire - Thu Apr 07, 8:10AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce the election of Steven Mintz to the Board of Directors at the Company's Annual and Special Meeting of Shareholders ("ASM" held on April 6, 2016. Mr. Mintz has been a Chartered Accountant since 1992 and received his BA (Economics and Accounting) from the University of Toronto in 1989. He obtained his Trustee in Bankruptcy license in 1995 and C.A. designation in June of 1992. From 1992 to 1997 he was employed by a boutique bankruptcy and insolvency firm and from 1989 until 1992 he did public accounting at a large accounting firm. Since January 1997 he has been a self-employed financial consultant serving both private individuals and companies as well as public companies in a variety of industries including mining, oil and gas, real estate and investment strategies. He has been a director of two CPCs, which have completed Qualifying Transactions. He has been, and currently is, an officer and director of several publicly traded companies. Mr. Mintz will hold office as a director until the next annual meeting. It is anticipated that Mr. Mintz will be appointed to the Corporation's audit committee and will qualify as an independent member in accordance with National Instrument 52-110 Audit Committees.

Portage's further investment in Biohaven
PR Newswire - Wed Mar 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that Biohaven Pharmaceutical Holding Company Limited ("Biohaven" recently raised approximately $ 3 million at a price of $3,500 per its common share. Portage subscribed for $ 1,001,000 and an independent director of Biohaven subscribed for the balance.

Portage Announces Proposed Private Placement
PR Newswire - Fri Mar 11, 8:00AM CST
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its development activities and finance clinical activities at Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" .

Portage's Biohaven orphan drug designation request granted for the treatment of spinocerebellar ataxia
PR Newswire - Thu Mar 03, 12:26PM CST
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that the Food and Drug Administration ("FDA" has granted the company's orphan drug designation request covering BHV-0223 for the treatment of spinocerebellar ataxia. Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve unsteady gait, speech difficulties, and clumsiness, potentially progressing to the stage of difficulty with swallowing and breathing due to degenerative changes in the brain and spinal cord. There is no cure for the hereditary SCAs and lifespan can be significantly shortened due to complications related to neurologic deficits. It is estimated that 150,000 people in the United States are affected by hereditary ataxias. Treatment is supportive and no medications are currently approved for this potentially debilitating condition.

Portage Issues Letter to Shareholders
PR Newswire - Fri Jan 15, 9:03AM CST
Portage Biotech Inc. ("Portage" or "the Company" ) (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), released a Letter to Shareholders today. A copy of the letter can be found on our web site at http://portagebiotech.com/news/letter-to-shar...-chairman/

Portage's Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
PR Newswire - Thu Nov 19, 3:30PM CST
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that preliminary results from a Phase I study with BHV-0223, a glutamate modulating agent, met its study objectives and supports advancing the asset into late phase clinical development. BHV-0223 is a unique formulation of a glutamate modulating agent that utilizes the Zydis® ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent. Agents that modulate glutamate neurotransmission may have therapeutic potential in multiple glutamatergically driven disease states including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, and numerous affective disorders like GAD and OCD.

Portage's Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Tue Oct 06, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the multiple dose portion of the Phase I study with BHV-0223, a glutamate modulating agent. Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company.

Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
PR Newswire - Thu Oct 01, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce a strategic alliance with ALS Biopharma LLC ("ALS" and Fox Chase Chemical Diversity Center, Inc. (FCCDC) to develop Biohaven's family of over 300 prodrugs of glutamate modulating agents as well as other innovative technologies. Under this agreement, Biohaven will provide $1.5M in research funding to FCCDC to advance a lead prodrug candidate to IND filing.
JNJ: 121.29 (-0.01), MRK: 57.94 (+0.33)

Portage's Biohaven Completes Single Dose Phase of Pharmacokinetic Trial with BHV-0223
PR Newswire - Mon Sep 21, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today that Biohaven has completed the single dose portion of its Phase I study of BHV-0223, a glutamate modulating agent. This summer, Biohaven filed an investigational drug application (IND) regarding BHV-0223 and obtained clearance from the U.S. Food and Drug Administration (FDA) to proceed with human testing. Portage holds 54% equity interest in Biohaven, a private company.

Portage's Biohaven's lead drug candidate clears FDA Investigational New Drug Application (IND) review and clinical studies to begin
PR Newswire - Mon Aug 24, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that the United States Food and Drug Administration has completed its review of Biohaven's Investigational New Drug Application (IND) for BHV-0223 and initial clinical studies in humans may begin. Portage holds 54% equity interest in Biohaven.

Portage's Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC
PR Newswire - Tue Aug 18, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U) and Biohaven Pharmaceutical Holding Company Limited ("Biohaven" are pleased to announce that Biohaven has acquired the world-wide intellectual property rights to a portfolio of over 300 prodrugs owned by ALS Biopharma, LLC ("ALSBio" . The prodrugs covered by the agreement were designed and prepared by Fox Chase Chemical Diversity Center, Inc. ("FCCDC" through a research program funded, in part, by the U.S. National Institutes of Health, through two peer-reviewed Small Business Innovation Research (SBIR) grants awarded to FCCDC. Most of the ALSBio prodrugs would be classified as New Molecular Entities (NMEs), and the intellectual property rights acquired by Biohaven include all future therapeutic indications.

Portage Invests in Sentien Biotechnologies Inc.
PR Newswire - Mon Aug 10, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF), is pleased to announce that it has made a Series A investment in Sentien Biotechnologies Inc.("Sentien" , a Medford, MA based regenerative medicine company. Portage is joined in this round of investment by Boehringer Ingelheim Venture Fund USA, Inc. ("BIVF" . Sentien will use the proceeds of its Series A round to fund its activities through a planned Phase I study of their lead product, the Sentinel(TM), a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI).

Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
PR Newswire - Thu Jul 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are pleased to announce that Biohaven has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to conduct clinical testing of BHV-0223. Portage holds 54% equity interest in Biohaven, a private company.

Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080
PR Newswire - Thu Jun 25, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (Canadian Securities Exchange: PBT.U , OTC Markets : PTGEF,), is pleased to announce that it has completed its non-brokered private placement raising US$5,155,080 through issuance of approximately 36.8 million common shares at US$0.14 each. The private placement was completed in two tranches, first tranche closed on June 15, 2015 as per our press release of June 16, 2015 and second and final tranche closed on June 24, 2015. The Company is debt free. Total number of common shares issued and outstanding after this private placement are 245,438,890.

Portage Closes First Tranche of Private Placement
PR Newswire - Tue Jun 16, 3:52PM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it has raised approximately $3.4 million by closing the first tranche of the non-brokered Private Placement previously announced on May 19, 2015. Pursuant to the terms of the private placement, Portage issued 23,881,214 common shares at a price of US$0.14 per share. All shares issued under private placement are subject to statutory hold periods. Two of the directors of the Company, Dr. Bailey and Mr. Mellon subscribed US$ 800,000 each.

Portage Biotech Announces Non-Brokered Private Placement - Video News Alert on InvestmentPitch.com
Newsfile Corp - Thu May 21, 10:08AM CDT
full story)

Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016
PR Newswire - Wed Apr 22, 10:00AM CDT
Biohaven to Initiate Pharmacokinetic and Biomarker Study with Lead Drug Development Candidate in 3Q2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 254

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 356

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 177

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Withdraw from Firms Vulnerable to AI Disruption

Updated Category News Views 397

The Growing Concern Over AI Disruption In recent times, there has been increasing unease among investors related to how artificial intelligence (AI) could potentially disrupt numerous industries. This anxiety has led to significant withdrawals from companies viewed as susceptible to these technological advancements. Identifying At-Risk Companies Firms such as Adobe Inc....

Continue Reading
Community Impact: Sunrise Maids Enhances Lives in Katy Area

Updated Category News Views 152

Sunrise Maids: Committed to Community Enrichment Sunrise Maids is not just another cleaning service; it embodies the spirit of giving back in Katy with its exceptional maid services. This locally operated company is well-known for its unwavering commitment to maintaining clean and healthy living spaces. But what sets Sunrise Maids apart is their strong dedication to...

Continue Reading
Air France-KLM Launches New Liquidity Contract with Rothschild

Updated Category News Views 188

Introduction of a New Liquidity Contract Air France-KLM is excited to announce its latest initiative to enhance market performance through a new liquidity contract. This partnership with Rothschild Martin Maurel is designed to fortify the trading environment for its shares, aligning with regulatory frameworks and practices. Details of the Liquidity Agreement The liquidity...

Continue Reading
Valeo's H1 2025 Performance: Insights and Financial Highlights

Updated Category News Views 499

Overview of Valeo's H1 2025 Financial Results Valeo has exhibited a notable improvement in its profitability metrics during the first half of 2025. The company's operating margin reached 4.5%, while their free cash flow stood at an impressive 252 million euros. This performance aligns well with Valeo's overall goals for profitability and cash generation for the year....

Continue Reading
Chinese Financial Landscape Shifts as Central Bank Takes Action

Updated Category News Views 90

Chinese Stocks Surge After Central Bank's Stimulus Measures Chinese stocks saw a notable increase after an unexpected announcement from the central bank, which introduced vital monetary stimulus measures. This decisive action is designed to revive the slowing economy and restore confidence among investors. Monetary Easing: A Comprehensive Approach The central bank...

Continue Reading